YIN Chun-yuan,LIU Jian-xun.Study on Compatibility Rules of TCM Compounds for Treatment of Arrhythmia Syndromes Based on National Patent[J].zhongguo zhongyiyao xinxi zazhi,2018,25(10):106-110.[doi:10.3969/j.issn.1005-5304.2018.10.023]
基于国家专利的中药复方治疗心律失常证候配伍规律研究
- Title:
- Study on Compatibility Rules of TCM Compounds for Treatment of Arrhythmia Syndromes Based on National Patent
- 文章编号:
- 1005-5304(2018)10-0106-05
- Keywords:
- arrhythmia; TCM compounds; patents; syndrome; compatibility rules
- 分类号:
- R2-05；R259.417
- 文献标志码:
- A
- 摘要:
- 目的 分析国家专利数据库中治疗心律失常中药复方用药规律，为新药研发提供参考。方法 计算机检索国家专利数据库2003年4月－2018年1月收录的治疗心律失常中药复方专利数据。采用中医传承辅助平台（V2.5）集成的药物频次、关联规则、复杂网络、熵聚类等方法，分析中药复方专利的主治证候及配伍规律。结果 纳入治疗心律失常的中药复方专利149项，包含药物614味。最常见的主治证候为心血瘀阻证（65次、43.62%）；高频药物有麦冬（43次、28.86%）、丹参（42次、28.19%）、炙甘草（37次、24.83%）、党参（34次、22.82%）、黄芪（34次、22.82%）等；常见药对有“麦冬-丹参”“炙甘草-党参”“麦冬-黄芪”等；常见角药有“炙甘草-麦冬-生地黄”“麦冬-丹参-人参”“麦冬-桂枝-五味子”等；重要关联规则有“炙甘草、生地黄→麦冬”“赤芍、人参→丹参”“柏子仁，黄芪→五味子”等；熵层次聚类得到的新处方有“党参、酸枣仁、人参、炙甘草”“琥珀、甘松、黄精、赤芍、山茱萸”等。结论 研发治疗心律失常的高效新药时，可考虑以心血瘀阻证为主治证候，以麦冬、丹参、炙甘草等为处方核心药物配伍加减。
- Abstract:
- Objective To analyze medication rules of TCM compounds forthe treatment of arrhythmia in the national patent database; To provide references for research and development of new medicine. Methods Computers were used to search the patent data about TCM compounds for the treatment of arrhythmia in National Patent Database from April 2003 to January 2018. Medicine frequency, association rules, complex networks, entropy clustering of Chinese auxiliary system (V2.5) were used to analyze treatment syndromes and compatibility rules. Results Totally 149 TCM compound patents for the treatment of arrhythmia were involved, including 614 kinds of Chinese materia medica. The most common treatment syndrome was heart-blood stasis syndrome (65 times, 43.62%). The medicines with high frequency were Ophiopogonis Radix (43 times, 28.86%), Salviae Miltiorrhizae Radix et Rhizoma (42 times, 28.19%), Glycyrrhizae Radix et Rhizoma Praeparata cum Melle (37 times, 24.83%), Codonopsis Radix (34 times, 22.82%), Astragali Radix (34 times, 22.82%) and so on. The common medicinal pairs were “Ophiopogonis Radix - Salviae Miltiorrhizae Radix”, “Glycyrrhizae Radix et Rhizoma Praeparata cum Melle - Codonopsis Radix”, and “Ophiopogonis Radix - Astragali Radix”. The common triple medicinal combinations were “Glycyrrhizae Radix et Rhizoma Praeparata cum Melle - Ophiopogonis Radix - raw Rehmanniae Radix”, “Ophiopogonis Radix - Salviae Miltiorrhizae Radix et Rhizoma - Ginseng Radix et Rhizoma”, and “Ophiopogonis Radix-Cinnamomi Ramulus-Schisandrae Chinensis Fructus”. The important association rules were “Glycyrrhizae Radix et Rhizoma Praeparata cum Melle, raw Rehmanniae Radix → Ophiopogonis Radix”, “Paeoniae Radix Rubra, Ginseng Radix et Rhizoma → Salviae Miltiorrhizae Radix”, and “Platycladi Semen, Astragali Radix → Schisandrae Chinensis Fructus”. New prescriptions obtained by entropy clustering were “Codonopsis Radix, Ziziphi Spinosae Semen, Ginseng Radix et Rhizoma, and Glycyrrhizae Radix et Rhizoma Praeparata cum Melle”, “Amber, Nardostachyos Radix et Rhizoma, Polygonati Rhizoma, Paeoni Aeradix Rubra, and Corni Fructus”. Conclusion When developing high-efficiency new medicines for the treatment of arrhythmia, heart-blood stasis syndrome is considered as the treatment syndrome. The core medicines in prescriptions should be modified compatibility of Ophiopogonis Radix, Salviae Miltiorrhizae Radix et Rhizoma and Glycyrrhizae Radix et Rhizoma Praeparata cum Melle.
参考文献/References:
[1] PIEPOLI M F, HOES A W, AGEWALL S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice[J]. Kardiol Pol,2016,74(9)：821-936. [2] 中国心血管病报告编写组.《中国心血管病报告2016》概要[J].中国循环杂志,2017,32(6)：521-530. [3] ZHANG X Y. Effect analysis of metoprolol combined with propafenone in the treatment of arrhythmia[J]. Clinical Research & Practice,2018,3(4)：19-20. [4] 郭建波,何庆勇,王阶,等.基于国家专利的中药复方治疗心力衰竭用药规律研究[J].中国中医药信息杂志,2018,25(8)：98-101. [5] 卢朋,李健,唐仕欢,等.中医传承辅助系统软件开发与应用[J].中国实验方剂学杂志,2012,18(9)：1-4. [6] 国家药典委员会.中华人民共和国药典：一部[M].北京：中国医药科技出版社,2015. [7] 钟赣生,刘树敏,宋捷民,等.中药学[M].北京：中国中医药出版社, 2013. [8] 胡大一.抗心律失常药物的使用原则[J].中国医刊，2001,36(6)：7-8. [9] 韦德慧,杨淑琴,刘菊芳,等.麦冬注射液的抗实验性心律失常和对离体心脏的作用[J].第一军医大学学报,1983,3(1)：23-26. [10] 张政.加减补阳还五汤治疗不稳定型心绞痛的临床观察[D].沈阳：辽宁中医药大学,2007.
相似文献/References:
[1]傅俊英,曹燕.美国授权的中药复方专利分析[J].中国中医药信息杂志,2011,18(1):2.[doi:10.3969/j.issn.1005-5304.2011.01.001]
[J].zhongguo zhongyiyao xinxi zazhi,2011,18(10):2.[doi:10.3969/j.issn.1005-5304.2011.01.001]
[2]张天嵩,张素,李秀娟,等.治疗肺纤维化中药复方用药规律的数据挖掘[J].中国中医药信息杂志,2011,18(2):31.[doi:10.3969/j.issn.1005-5304.2011.02.014]
ZHANG Tian-song,ZHANG Su,LI Xiu-juan,et al.Data Mining of the Regularity of Compound Herbal Formulae for Pulmonary Fibrosis[J].zhongguo zhongyiyao xinxi zazhi,2011,18(10):31.[doi:10.3969/j.issn.1005-5304.2011.02.014]
[3]姜旭光,姜明霞,荆雪宁,等.中药合剂治疗佐剂性关节炎大鼠的拆方实验研究[J].中国中医药信息杂志,2008,15(2):18.
JIANG Xu-guang,JIANG Ming-xia,JING Xue-ning,et al.Experimental Research on Adjuvant Arthritis Treated with Different Combinative Herbal Mixture[J].zhongguo zhongyiyao xinxi zazhi,2008,15(10):18.
[4]周鹏,胡素敏,佟海英,等.中药对模拟失重大鼠骨骼-肌肉系统干预的初步研究[J].中国中医药信息杂志,2008,15(5):27.
ZHOU Peng,HU Su-min,TONG Hai-ying,et al.Preliminary Study on Effect of Chinese Herb Medicine Compound on Bone-muscle System in Rats under Simulated Weightlessness[J].zhongguo zhongyiyao xinxi zazhi,2008,15(10):27.
[5]吕祥,指导：李柏.中药复方拆方研究进展[J].中国中医药信息杂志,2008,15(10):105.
[J].zhongguo zhongyiyao xinxi zazhi,2008,15(10):105.
[6]张文宗,指导：林钟香.林钟香治疗病毒性心肌炎后遗症心律失常临床经验分析[J].中国中医药信息杂志,2008,15(11):88.
[J].zhongguo zhongyiyao xinxi zazhi,2008,15(10):88.
[7]李秀娟,聂永红,张素,等.基于数据挖掘探讨胃食管反流病中药复方用药规律[J].中国中医药信息杂志,2011,18(8):21.[doi:10.3969/j.issn.1005-5304.2011.08.009]
LI Xiu-juan,NIE Yong-hong,ZHANG Su,et al.Data Mining of the Regularity of Compound Herbal Formulae for Gastroesophageal Reflux Disease[J].zhongguo zhongyiyao xinxi zazhi,2011,18(10):21.[doi:10.3969/j.issn.1005-5304.2011.08.009]
[8]樊琴.心安Ⅰ号治疗冠心病心律失常疗效观察[J].中国中医药信息杂志,2011,18(11):71.[doi:10.3969/j.issn.1005-5304.2011.11.029]
[J].zhongguo zhongyiyao xinxi zazhi,2011,18(10):71.[doi:10.3969/j.issn.1005-5304.2011.11.029]
[9]张兆元.治肝法临床应用举隅[J].中国中医药信息杂志,2007,14(6):82.
[J].zhongguo zhongyiyao xinxi zazhi,2007,14(10):82.
[10]李晓杰,车景超.中药抗肝纤维化研究进展[J].中国中医药信息杂志,2007,14(9):94.
[J].zhongguo zhongyiyao xinxi zazhi,2007,14(10):94.
备注/Memo
基金项目：国家重点基础研究发展计划（2015CB554405）
更新日期/Last Update:
2018-09-19